An ongoing dialogue on HIV/AIDS, infectious diseases,
October 29th, 2011
Will An Antiretroviral Patch Help Adherence? Doubtful …
This little nugget came up recently, found by our Journal Watch Executive Editor:
Preliminary research suggests that a patch could deliver an AIDS drug to patients … The researchers successfully used transdermal patches to administer 96 percent of an AIDS drug to simulated skin over a week. “Still, the important limitation of pills, regardless of how few there are or even how minimal the side effects, is adherence,” Johnston [the investigator] noted. Research has shown that many patients, if not most, don’t take their pills all the time.
Setting aside for a moment the fact that most patients actually do take their medications just fine, thank you — and that this particular transdermal HIV drug delivery system hasn’t even been tested on animals, let alone humans — I have always wondered about the assumption that novel drug delivery systems would improve adherence.
Seems to me that the major problem with non-adherent patients isn’t that they can’t take pills.
It’s that they won’t take them.
And I strongly suspect that most would make the same choice when it comes to putting on a patch every day (or even every week).
Categories: HIV, Patient Care, Research
Tags: antiretroviral therapy, drug delivery systems, HIV
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
2 Responses to “Will An Antiretroviral Patch Help Adherence? Doubtful …”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
- Learning the Names of HIV Drugs Is Horribly Difficult — Here’s Why
- SNAP Trial Helps Resolve Long-Running Controversies Over Management of Staph Bacteremia
- The Mystery of the Isolated Hepatitis B Core Antibody, Solved
- DOTS: Optimism Around a “Negative” Dalbavancin Trial
- How to Figure Out the Length of Antibiotic Therapy
-
From the Blog — Most Recent Articles
- Farewell to This Blog — and Hello to NEJM Voices March 2, 2026
- Some Ruminations on CROI — Still the Best HIV Meeting February 26, 2026
- Two Things Can Be True: The FDA Process Was Inconsistent, and the mRNA Vaccine Data Were Disappointing February 17, 2026
- Sometimes You Just Need to Get Input from a Real Human Being February 12, 2026
- Mystifying Abbreviations — Infectious Diseases Edition February 4, 2026
FROM NEJM — Recent Infectious Disease Articles- Oya Virus in a Patient with Severe Hepatitis, Enteritis, and Coagulopathy September 24, 2026Oya virus, an orthobunyavirus, was identified in a 54-year-old woman who had sepsis-like symptoms, including leukocytosis, thrombocytopenia, elevated liver-function values, and disseminated intravascular coagulation.
- Cerebral Schistosomiasis September 24, 2026A rice farmer presented to the ED after a 1-minute episode of arm and leg shaking on the right side. MRI showed linear enhancement associated with a cluster of enhancing nodules and surrounding edema in the left frontal lobe.
- The End of the War on Biomedical Science? September 24, 2026The turmoil of the past 20 months has inflicted lasting damage on American science and public health. But history and recent events suggest that the attacks will subside.
- Human Adenovirus B3–Induced Immune Thrombocytopenia and Thrombosis September 17, 2026Virus-induced immune thrombocytopenia and thrombosis after HAdV-B3 infection supports a shared platelet factor 4–targeted immune mechanism linking natural adenovirus infection and adenoviral vector–associated disease.
- Honoring the Legacy of the HIV Epidemic September 17, 2026Progress against the U.S. HIV epidemic is stalling, owing in part to government attacks and fear. But clinicians, patients, and activists can learn from the epidemic’s early heroes and find ways to advance.
- Oya Virus in a Patient with Severe Hepatitis, Enteritis, and Coagulopathy September 24, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

Perhaps most patients in that Baltimore, MD study take their medications just fine… what about those at high risk for nonadherence? Putting on a patch once a week (perhaps supervised during a home visit by a health worker) could be a real improvement over twice-daily pills for some PLH whom I have encountered in a developing country setting. It could certainly be easier for those with a variable sleep or work schedule. I think it would be a simpler option for me if I were on ART.
Hi Amy,
Agree it might be handy … for those who agree to do it!
I also think that Baltimore study is pretty representative of a very challenging group of patients — here’s my review of it:
http://cid.oxfordjournals.org/content/53/6/605.full
My rough estimate is that around 10-20% of HIV patients don’t take their meds, but they loom very large in our minds since we spend so much time agonizing over them!
Paul